Active Pharmaceutical Ingredients (API) in Pharma: Manufacturing, ICH Q7, GMP, Impurities & FDA/Health Canada

 

Published by: Pharma Quality System Editorial Team • Editorial basis: FDA/ICH Q7 and Q11, ICH Q6A and quality-system principles, FDA API CGMP enforcement, and Health Canada GUI-0104 and Drug Establishment Licence requirements

DRUG SUBSTANCE • ICH Q7 • ICH Q11 • GMP • IMPURITIES • PROCESS CONTROL • RELEASE • SUPPLY CHAIN

An active pharmaceutical ingredient is the substance that provides the intended pharmacological activity of a medicine. Its quality is built through controlled starting materials, process understanding, impurity control, suitable equipment, validated critical steps, laboratory testing, quality-unit oversight, documentation and lifecycle management.

Quick answer

Active pharmaceutical ingredients (APIs), also called drug substances, are substances or mixtures intended for use in manufacturing a drug product and that become the active ingredient of that product. API manufacturing can involve chemical synthesis, extraction, cell culture/fermentation, recovery from natural sources, purification, crystallization, drying, milling and packaging. For the U.S. market, FDA uses ICH Q7 expectations when assessing API CGMP. In Canada, Health Canada GUI-0104 interprets GMP requirements for APIs and API intermediates.

Important regulatory nuance:
Do not simply apply every finished-dosage-form requirement in 21 CFR Part 211 to API manufacturing as if the frameworks were identical. FDA states that it considers the expectations in ICH Q7 when determining whether APIs are manufactured in conformance with CGMP. Q7 is specifically written for API manufacturing, while finished pharmaceuticals are governed by the applicable finished-product CGMP framework. The point at which GMP begins in an API process also depends on the process and the justified API starting material.

Table of Contents

1. What Is an Active Pharmaceutical Ingredient?
2. API vs Drug Product vs Excipient
3. ICH Q7 and API GMP
4. API Starting Materials and the GMP Starting Point
5. Main API Manufacturing Routes
6. Typical API Manufacturing Process
7. Raw Materials, Suppliers and Incoming Controls
8. Critical Process Controls and In-Process Testing
9. Impurity Control in APIs
10. Solid State, Particle Size and Physical Properties
11. Facilities, Equipment and Contamination Control
12. Qualification, Cleaning and Process Validation
13. API Specifications and Quality Control Testing
14. OOS, Deviations and Investigations
15. Reprocessing vs Reworking
16. Stability, Retest Dates and Expiry Dates
17. API Packaging, Labeling, Storage and Distribution
18. Quality Unit and Documentation
19. Contract Manufacturing and API Supply Chain
20. Drug Master Files and U.S. Regulatory Context
21. Health Canada API Requirements
22. 2026 FDA API Warning-Letter Lessons
23. Common API GMP Mistakes
24. API Interview Questions
25. FAQ

What Is an Active Pharmaceutical Ingredient (API)?

An active pharmaceutical ingredient (API), also called a drug substance, is any substance or mixture of substances intended for use in the manufacture of a drug product and that becomes an active ingredient when used in the drug. Its purpose is to provide pharmacological activity or another direct effect related to diagnosis, treatment, mitigation, cure, prevention of disease, or the structure or function of the body.

The API is therefore the active chemical or biological component of a medicine, but it is not usually the finished medicine that the patient takes. A tablet may contain only a relatively small amount of API surrounded by excipients. An injectable product may contain the API dissolved or suspended in a sterile formulation. The finished drug product adds formulation, dosage form, packaging and administration characteristics around the drug substance.

Practical example:
In a 500 mg tablet, “500 mg” may refer to the labeled amount of the active drug substance per tablet. The tablet also contains excipients that support flow, compression, disintegration, stability, coating or other formulation functions. The API provides the intended pharmacological effect; the excipients help make a usable and manufacturable dosage form.

API vs Drug Product vs Excipient

Term	Meaning	Example
API / Drug Substance	The active substance intended to provide the pharmacological activity.	A purified active chemical compound.
Excipient	An inactive formulation component used for technological or product-performance purposes.	Binder, filler, lubricant, coating polymer.
Drug Product	The finished dosage form containing the API, usually with excipients, in its final or marketed presentation.	Tablet, capsule, vial, oral solution.
Intermediate	Material produced during API processing that must undergo further molecular change or purification before becoming the API.	Isolated synthesis intermediate.

For a broader view of how drug substances become finished dosage forms, see Pharmaceutical Manufacturing Process.

ICH Q7 and GMP for Active Pharmaceutical Ingredients

ICH Q7 is the central international GMP guideline for API manufacturing. FDA's final Q7 guidance explains expectations for quality management, personnel, buildings and facilities, process equipment, documentation, materials management, production and in-process controls, packaging and labeling, storage and distribution, laboratory controls, validation, change control, rejection and reuse of materials, complaints and recalls, contract operations, and agents or distributors.

Q7 applies to APIs manufactured by routes such as chemical synthesis, extraction, cell culture or fermentation, recovery from natural sources, or combinations of these approaches. It also explains that GMP stringency should increase as manufacturing proceeds from earlier API steps toward final processing, purification and packaging.

Sterile API nuance:
Q7 applies to sterile API manufacture up to the point immediately before the API is rendered sterile. Sterilization and aseptic processing are handled under the applicable local GMP expectations for sterile drug manufacturing rather than by treating Q7 as the complete sterile-processing standard.

For a broader GMP overview, see GMP in Pharmaceutical Industry.

API Starting Materials and the GMP Starting Point

One of the most important API concepts is the API starting material. Q7 describes it as a raw material, intermediate or API used in production of an API and incorporated as a significant structural fragment into the API structure. A company should designate and document the rationale for the point at which API production begins.

This is not a paperwork detail. The selected starting material affects:

• where full Q7 GMP expectations begin;
• how much process understanding and impurity fate information is available;
• what manufacturing steps are included in the regulatory drug-substance process description;
• supplier and material controls;
• the ability to control impurities introduced or generated upstream.

ICH Q11 complements Q7 by describing development and manufacture of drug substances and by clarifying the selection and justification of starting materials. Q11's dedicated questions and answers were developed because starting-material justification required additional global clarification.

Key principle:
Selecting a late-stage material mainly to reduce the apparent GMP portion of the process is not a sound regulatory strategy. Starting-material selection should be scientifically justified and should leave enough of the drug-substance process under appropriate control to understand and manage quality and impurities.

Main API Manufacturing Routes

API manufacturing is not a single universal process. The route depends on the molecule and platform.

1. Chemical Synthesis

Small-molecule APIs are commonly produced through sequences of chemical reactions, phase separations, extractions, distillation or solvent exchange, crystallization, filtration, washing, drying and physical processing. Critical risks can include reaction selectivity, by-products, residual starting materials, residual solvents, catalysts or metals, polymorphic form, particle size and degradation.

2. Fermentation and Cell Culture

Biological or fermentation-derived drug substances can involve cell-bank control, inoculation and expansion, fermentation or cell culture, harvest, clarification, isolation and purification. Depending on the platform, process-related impurities, bioburden, endotoxin, host-cell proteins, residual media components and viral safety can require specialized controls.

3. Extraction or Recovery from Natural Sources

Some drug substances are recovered from botanical, animal or other natural-source materials. Source variability, contamination, extraction selectivity, purification and traceability may become major quality considerations.

4. Physical Processing of the API

Even after the chemical or biological structure is established, physical processing such as milling, micronization, sieving, granulation or controlled crystallization can materially affect downstream drug-product performance. These steps should be controlled according to their effect on API quality and intended use.

Typical API Manufacturing Process

A generic small-molecule API process may look like:

1. Approved starting materials and reagents: receipt, identification, quarantine, sampling, testing and release.
2. Reaction or transformation: controlled addition, temperature, pressure, pH, agitation, reaction time and endpoint, as applicable.
3. Work-up: quench, extraction, phase separation, concentration, solvent exchange or other operations.
4. Intermediate isolation: crystallization, precipitation, filtration, washing, centrifugation or drying.
   
   
   
   
   
5. Further reaction/purification: additional chemistry or purification steps until the required impurity profile is achieved.
6. Final API isolation: final crystallization/precipitation and controlled separation.
7. Drying: removal of water or solvents to a justified level.
8. Physical processing: milling, micronization, sieving or blending when required.
9. QC testing: identity, assay, impurities and other approved specification tests.
10. Quality-unit disposition: review of batch data, deviations, investigations and laboratory results before release or rejection.
11. Packaging, labeling, storage and distribution: protection of identity, purity and stability through the supply chain.

The exact process may be shorter, longer or completely different for biologics, peptides, fermentation products or naturally derived APIs.

Raw Materials, Suppliers and Incoming Controls

API quality can be compromised before the first manufacturing step if starting materials, reagents, solvents, catalysts, processing aids or water are not adequately controlled. Q7 expects incoming materials to be identified, appropriately examined or tested, quarantined before release and managed under written systems.

Risk-based material control can include:

• approved suppliers and quality agreements;
• known manufacturer identity for critical materials;
• incoming container examination and tamper evidence;
• identity testing and other appropriate testing;
• supplier CoA verification and reliability assessment;
• storage and status controls;
• traceability to API batch records;
• change control when the source of a critical raw material changes.

FDA's 2026 API enforcement continued to emphasize that inadequate incoming-material controls can create direct quality and safety risks, including use of mislabeled or inadequately evaluated raw materials.

Critical Process Controls and In-Process Testing

Not every parameter is critical, and not every in-process test requires the same level of control. The purpose of development and process understanding is to identify which variables can affect API quality and then build a suitable control strategy.

Depending on the process, important controls may include:

• raw-material charge quantities and sequence;
• reaction temperature and pressure;
• pH;
• agitation or mixing conditions;
• reaction endpoint;
• hold times;
• crystallization temperature profile and seeding;
• filtration and washing conditions;
• drying temperature, vacuum and endpoint;
• milling or micronization settings;
• bioburden/endotoxin where relevant;
• in-process impurity or assay measurements.

Q7 specifically expects critical in-process controls and critical process monitoring to be written and approved by the quality unit. Process adjustments may be made within pre-established approved limits, but results should be documented as part of the batch record.

Impurity Control in Active Pharmaceutical Ingredients

Impurity control is one of the defining technical challenges of API development and manufacturing. A high assay alone does not prove that an API has an acceptable quality profile.

Potential impurity sources include:

• unreacted starting materials;
• reaction by-products;
• intermediates;
• degradation products;
• reagents and catalysts;
• inorganic residues;
• residual solvents;
• process-related contaminants;
• cross-contamination from other products or equipment;
• microbiological or endotoxin contamination where relevant.

ICH Q6A explains that drug-substance specifications form part of the overall control strategy, while Q7 expects API specifications to include appropriate control of impurities such as organic impurities, inorganic impurities and residual solvents. Impurity control should be linked to process knowledge: where the impurity comes from, how it behaves across the process, how effectively it is purged, how it is measured and what acceptance criteria are justified.

Important:
“Not detected in one batch” is not the same as demonstrating that an impurity is reliably controlled. Robust impurity control uses process understanding, appropriate analytical capability, justified specifications and lifecycle monitoring.

Solid State, Particle Size and Other Physical API Properties

The chemical identity of an API is only part of its performance. For some drug substances, physical properties can affect manufacturability, stability, dissolution or drug-product performance.

Examples include:

• polymorphic or crystalline form;
• hydrate or solvate state;
• particle-size distribution;
• surface area;
• bulk/tapped density;
• flow behavior;
• hygroscopicity;
• water content.

Whether these become formal release specifications, in-process controls or characterization tests depends on the molecule, process, drug product and demonstrated impact on quality.

Facilities, Equipment and Contamination Control in API Manufacturing

API plants often use reactors, centrifuges, filters, dryers, mills, solvent systems, utilities and multi-purpose equipment. The facility and equipment design must support cleaning, maintenance, appropriate material and personnel flow, and prevention of contamination or mix-ups.

Key controls can include:

• suitable materials of construction;
• equipment identification and status;
• calibration and preventive maintenance;
• cleaning procedures and verified cleanliness;
• closed processing or containment where risk requires it;
• controls for highly sensitizing or potent materials;
• water and utility quality appropriate to process use;
• environmental controls that reflect the stage and contamination risk.
  
  
  
  
  
  
  
  
  
  

See also Equipment Qualification in Pharmaceutical Industry and Cleaning Validation in Pharma.

Qualification, Cleaning Validation and Process Validation for APIs

Q7 expects critical equipment and ancillary systems to be qualified, and critical process steps that impact API quality to be validated. The amount of validation should reflect process knowledge and risk rather than a generic checklist copied across products.

A typical validation framework may include:

• equipment qualification for critical manufacturing and support equipment;
• analytical procedure validation or qualification appropriate to the method's intended use;
• cleaning validation where carryover or contamination risk requires demonstrated control;
• process validation for critical commercial API manufacturing steps;
• computerized-system controls for GMP-relevant electronic records and process/laboratory systems;
• requalification or revalidation when changes or performance history justify it.
  

Q7 also recognizes development-stage reality: full process validation is generally not appropriate for an API process still changing in early clinical development, while commercial API manufacture requires a validated and controlled process.

For validation lifecycle concepts, see Process Validation in Pharma.

API Specifications and Quality Control Testing

API release depends on an approved specification and suitable analytical methods. The exact tests depend on the drug substance, manufacturing route and registered requirements.

Common API specification elements may include:

• description or appearance;
• identification;
• assay or potency;
• organic impurities / related substances;
• residual solvents;
• water or loss on drying;
• inorganic residues or other process-specific impurities;
• particle size or physical form where quality-relevant;
• microbiological quality or endotoxin where applicable;
• other compendial or product-specific tests.

Q7 expects laboratory controls to be documented at the time of performance and any OOS result to be investigated according to a procedure. Primary and secondary reference standards also require appropriate controls.

For chromatographic testing and laboratory controls, see HPLC in Pharmaceutical Quality Control.

OOS Results, Deviations and API Investigations

API manufacturers should have written systems for investigating critical deviations and failures of intermediates or APIs to meet specifications. Investigations should be scientifically meaningful, appropriately scoped and connected to corrective and preventive action when needed.

Weak practices include:

• invalidating an OOS result without scientific evidence;
• retesting repeatedly until a passing result appears;
• stopping at “operator error” without evaluating system causes;
• failing to evaluate other affected batches or materials;
• implementing CAPA that addresses only the symptom;
• closing investigations without effectiveness follow-up.

Related guides: OOS in Pharmaceutical Industry, Root Cause Analysis in Pharma, and CAPA in Pharmaceutical Industry.

Reprocessing vs Reworking in API Manufacturing

Q7 makes an important distinction between reprocessing and reworking.

Reprocessing generally means returning an intermediate or API to the process and repeating a step that is already part of the established manufacturing process, such as repeating crystallization, filtration, distillation or another routine processing step. It can be acceptable when controlled by established procedures and scientifically justified.

Reworking involves subjecting material that does not meet standards or specifications to one or more processing steps that differ from the established manufacturing process. Because this can introduce new risks, Q7 expects investigation, evaluation and appropriate validation before relying on a reworked process.

Do not use reprocessing or reworking as a routine substitute for a capable process.
Recurring recovery of failing material is a signal to investigate process design, variability and the underlying quality system.

API Stability, Retest Dates and Expiry Dates

API stability programs support storage conditions and assignment of a retest date or, where appropriate, an expiry date. These terms should not be treated as automatically interchangeable.

A retest date means the material should be re-examined to confirm that it still meets specification before use after the assigned period. An expiry date defines the period after which the API should not be used. Q7 includes specific expectations for stability monitoring, storage conditions and transfer of retest/expiry information through the supply chain.

Stability-indicating methods should be suitable for detecting meaningful change. Repackaging an API into a different container type can require additional stability justification because the packaging system itself may affect protection from moisture, light, oxygen or contamination.

See Stability Testing in Pharmaceutical Industry.

API Packaging, Labeling, Storage and Distribution

Packaging is part of API quality protection. Containers should provide adequate protection against deterioration or contamination during transportation and recommended storage. Packaging and labeling operations should prevent mix-ups, loss of identity and incorrect status.

Controls can include:

• approved packaging specifications;
• container cleanliness and suitability;
• label issuance and reconciliation;
• API name, batch/lot number and status identification;
• storage temperature or humidity where required;
• retest or expiry date information;
• traceability through agents, brokers, repackers and distributors;
• quality-information transfer to customers.

Quality Unit Responsibilities and API Documentation

Q7 expects an independent quality unit with authority appropriate to API operations. Quality is not the sole responsibility of QA or QC, but the quality unit plays a central oversight and disposition role.

Responsibilities include, as applicable:

• release or rejection of APIs and intermediates;
• approval of specifications and master production instructions;
• review of completed batch production and laboratory records;
• oversight of deviations, OOS investigations and CAPA;
• approval of critical changes;
• supplier and contract-operation oversight;
• internal audits/self-inspection;
• product quality review;
• ensuring GMP records are complete, traceable and retained.

Electronic records, chromatographic data, audit trails and computerized process systems should also be governed to preserve data integrity. See Data Integrity in Pharmaceutical Industry.

Contract API Manufacturing, Testing and Supply-Chain Control

Outsourcing an API operation does not outsource responsibility for quality. Q7 expects companies to evaluate contractors, define GMP responsibilities in written agreements and maintain appropriate oversight. Contractors should not make unapproved changes to processes, equipment, test methods, specifications or other contractual quality requirements.

Critical supply-chain controls include:

• knowing the original API manufacturer;
• maintaining traceability through brokers/repackagers;
• quality agreements;
• change notification;
• complaint and recall communication;
• storage and transport controls;
• GMP qualification of testing laboratories and contractors.

API Drug Master Files (DMFs) in the United States

A Drug Master File (DMF) allows a holder to submit confidential manufacturing, controls and other technical information to FDA that can be referenced by an authorized drug-application applicant without directly disclosing all proprietary information to that applicant.

FDA identifies Type II DMFs as the DMF type used for active pharmaceutical ingredients. A Type II API DMF can support applications such as ANDAs when the DMF holder provides authorization for reference. A DMF does not itself represent approval of an API as a standalone commercial product; FDA reviews the referenced information in the context of the applicable drug application and regulatory process.

CMC connection:
ICH Q11 describes development and manufacture of drug substances and the type of drug-substance manufacturing information that supports CTD Module 3. This makes API process understanding, control strategy, starting-material justification and impurity knowledge important not only for GMP but also for regulatory CMC submissions.

Health Canada Requirements for Active Pharmaceutical Ingredients

Health Canada's GUI-0104 - Good manufacturing practices for active pharmaceutical ingredients is the central Canadian GMP guidance for APIs and API intermediates. It interprets Part C, Division 2 of the Food and Drug Regulations and is aligned with internationally harmonized ICH Q7 concepts.

GUI-0104 addresses areas such as:

• pharmaceutical quality systems;
• quality-unit and production responsibilities;
• personnel, buildings, utilities and equipment;
• documentation and records;
• materials management;
• production and in-process controls;
• packaging and labeling;
• storage and distribution;
• laboratory controls;
• validation;
• change control;
• rejection and reuse of materials;
• complaints, recalls, contractors and supply-chain activities.

Canadian establishments conducting licensable drug activities must also meet applicable Drug Establishment Licence (DEL) requirements. Health Canada's current DEL application framework includes specific sections for domestic and foreign API-related activities.

For finished-product Canadian GMP expectations, see Health Canada GMP Guidelines (GUI-0001).

2026 FDA API Warning-Letter Lessons

Recent FDA enforcement provides practical examples of where API quality systems fail. These letters should not be treated as new regulations, but they show how FDA applies CGMP expectations in real facilities.

2026 FDA example	Lesson for API manufacturers
Almon Healthcare - July 2026	FDA cited significant API CGMP deviations and emphasized incoming-material controls and adequate quality-unit oversight. The letter specifically referenced Q7 expectations.
Shimoga Chemicals - July 2026	FDA linked API CGMP deficiencies with quality-system and data-integrity concerns and referenced a voluntary API recall.
Hubei Gedian Humanwell - June 2026	FDA emphasized management oversight, quality-unit authority and system-level remediation rather than isolated fixes.
Flowchem Pharma - March 2026	FDA cited inadequate cleaning and maintenance of non-dedicated API equipment, including residues on product-contact surfaces, reinforcing contamination-control expectations.

Common API GMP Mistakes

1. Weak starting-material justification: defining the GMP starting point without enough scientific and impurity-control rationale.
2. Poor supplier control: relying on documents without adequate identity, testing or supplier-reliability systems.
3. Weak impurity knowledge: testing only final assay while failing to understand impurity formation and purge.
4. Inadequate cleaning: declaring multi-purpose equipment clean without a robust procedure or evidence.
5. Uncontrolled process adjustments: operators changing conditions outside approved limits without investigation or change control.
6. Weak OOS investigations: retesting until passing results are obtained.
7. Human error as the default root cause: failing to evaluate procedural, equipment, training or system contributors.
8. Routine reprocessing: repeatedly recovering failures instead of correcting the underlying process.
9. Data-integrity gaps: incomplete records, uncontrolled electronic data, missing audit-trail review or undocumented calculations.
10. Contractor blind spots: assuming the API customer or contractor is solely responsible for outsourced quality activities.

API Manufacturing Interview Questions

1. What is the difference between an API and a drug product?
An API is the active drug substance that provides the pharmacological activity; the drug product is the finished dosage form containing that API and other formulation components.

2. What is ICH Q7?
It is the international GMP guideline for manufacturing active pharmaceutical ingredients under an appropriate quality-management system.

3. What is an API starting material?
A defined raw material, intermediate or API introduced into the API process that contributes a significant structural fragment and marks a scientifically justified regulatory/GMP starting point.

4. Why is impurity profiling important?
Because API quality depends not only on assay but also on controlling process-related and degradation impurities that can affect safety, quality and downstream product performance.

5. What is the difference between reprocessing and reworking?
Reprocessing repeats an established process step; reworking uses processing outside the established manufacturing process and therefore requires stronger evaluation and justification.

6. Why can API particle size matter?
It can affect flow, blending, dissolution, bioavailability or drug-product manufacturing, depending on the product and formulation.

7. What is a Type II DMF?
In FDA's DMF system, Type II covers an active pharmaceutical ingredient and allows authorized reference to confidential technical information supporting a drug application.

Frequently Asked Questions About APIs

Is API the same as drug substance?

In pharmaceutical quality and ICH terminology, the terms are commonly used interchangeably. Q7 explicitly uses “Active Pharmaceutical Ingredient (API) (or Drug Substance).”

Is an API the same as a raw material?

No. Raw materials can include starting materials, reagents, solvents and processing aids used to manufacture the API. The API is the active drug substance produced through the controlled manufacturing process.

Does FDA require ICH Q7 for API manufacturers?

FDA states that it considers the expectations outlined in ICH Q7 when determining whether APIs are manufactured in conformance with CGMP. FDA warning letters to API manufacturers routinely reference Q7 as the relevant API CGMP guidance.

Does every API require the same tests?

No. Specifications and analytical controls depend on the API, route of manufacture, impurity profile, physical properties, compendial requirements, intended drug product and registered regulatory commitments.

Can an API be released based only on a Certificate of Analysis?

The final API manufacturer should have appropriate release testing, specifications, quality-unit review and documented controls. Downstream users may rely on supplier information only within a justified supplier/material-control system; a CoA does not eliminate the need for appropriate identity and supplier-reliability controls.

What is the difference between a retest date and an expiry date?

A retest date indicates when the API should be retested to confirm continued suitability before use. An expiry date indicates the time after which the API should not be used. The applicable assignment should be supported by stability data and the product/material strategy.

Does API manufacturing need process validation?

Critical commercial API manufacturing steps that affect quality should be validated under Q7. During early clinical development, full process validation may not yet be appropriate while the process is still evolving.

Key Takeaways

• API and drug substance are generally equivalent terms in ICH pharmaceutical quality usage.
• ICH Q7 is the core GMP framework for API manufacture; ICH Q11 adds drug-substance development and starting-material guidance.
• The GMP starting point in API manufacturing must be scientifically justified.
• API quality is determined by process control and impurity knowledge, not assay alone.
• Material controls, equipment cleanliness, validation, laboratory controls and quality-unit oversight are central to reliable API manufacturing.
• Reprocessing and reworking are not interchangeable concepts.
• Stability supports justified retest or expiry dating.
• In the U.S., Type II DMFs are used for API information; in Canada, GUI-0104 and applicable DEL requirements are central to API compliance.
  
  
  
  
  

Final perspective

A reliable API process is not defined only by the final assay result. It is defined by a controlled manufacturing history: justified starting materials, understood chemistry or biology, controlled impurities, suitable equipment, reliable analytical data, documented decisions and a quality system capable of keeping the process in control across the lifecycle.

Official Regulatory Sources

• FDA / ICH Q7 — Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
• FDA / ICH Q7 — Questions and Answers
• FDA / ICH Q11 — Development and Manufacture of Drug Substances
• FDA / ICH Q11 — Questions and Answers
• FDA / ICH Q6A — Specifications
• FDA — Types of Drug Master Files
• Health Canada — GUI-0104 Good Manufacturing Practices for Active Pharmaceutical Ingredients
• Health Canada — Drug Establishment Licence Application Requirements
• FDA Warning Letter — Almon Healthcare Private Limited (2026)
• FDA Warning Letter — Shimoga Chemicals (2026)
• FDA Warning Letter — Hubei Gedian Humanwell Pharmaceutical (2026)
• FDA Warning Letter — Flowchem Pharma Private Limited (2026)

Editorial note: This article is educational and does not replace product-specific regulatory requirements, approved applications, current pharmacopeial standards, company procedures, or advice from the applicable regulatory authority.